NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.

Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.

Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.